web analytics

News & Press



CTK’s Aridia Real-Time COVID-19 PCR Tests detect new SARS-CoV-2 variants, including U.K., South Africa, Brazil, California, Nigeria, and India/Delta variants

CTK’s goal during the current COVID-19 pandemic is to provide quality diagnostic tools for the detection of SARS-CoV-2, such as the Aridia Real-Time COVID-19 PCR Test. As new SARS-CoV-2 variants are identified, CTK has been working on confirmation studies to ensure that the performance of the Aridia COVID-19 Real-Time PCR Test isn’t affected by these mutations. The Aridia COVID-19 Real-Time.... Read Full Article >



CTK’s OnSite COVID-19 Ag Rapid Test is on the EU Common List and EU Mutual Recognition List!

CTK’s OnSite® COVID-19 Ag Rapid Test is on the EU Common List and EU Mutual Recognition List! Our test meets the requirements for both Nasal and Nasopharyngeal specimens for individuals suspected of COVID-19 within the first seven days of the onset of symptoms. The EU Common List requires that rapid antigen tests meet a minimum performance of ≥ 90% sensitivity.... Read Full Article >



UPDATE: OnSite Covid-19 Ag Rapid Tests detect new SARS-CoV-2 variants – California, Nigeria, and India/Delta variants

As more and more variants are emerging, CTK’s commitment to ensure that CTK’s OnSite® COVID-19 Ag Rapid Test isn’t affected by these mutations is ongoing. We analyzed the NP mutations present in the California, Nigeria, and India/Delta variants and mapped them on the SARS-CoV-2 NP protein recognized by CTK’s OnSite® COVID-19 Ag Rapid Test using ELISA and peptide scanning. We found that.... Read Full Article >



How CTK is Supporting Current COVID-19 Market Needs

CTK’s goal is to provide a Complete COVID-19 Diagnostic Solution and support market needs as the COVID-19 pandemic progresses. The COVID-19 market is ever-changing but currently can be segmented into: Increase testing needs as cases continue to fluctuate around the world:  CTK’s Aridia COVID-19 Real-Time PCR Test detects SARS-CoV-2 B.1.1.7 with the same LOD (≤ 10 RNA copies per reaction) as.... Read Full Article >



CTK’s OnSite Covid-19 Ag Rapid Tests detect newly identified U.K., South Africa, and Brazil SARS-CoV-2 variants

In December 2020, CTK shared that we had no reason to believe that the U.K. variant would affect the OnSite COVID-19 Ag Rapid Test’s performance, and we would work on confirmation studies.  Since then, multiple SARS-CoV-2 variants have been circulating globally, which led us to include them in our confirmation studies. The OnSite COVID-19 Ag Rapid Test detects the presence.... Read Full Article >



Ongoing studies indicate that CTK’s OnSite Covid-19 IgG/IgM Rapid Tests detect antibodies in response to COVID-19 vaccines

CTK’s OnSite COVID-19 IgG/IgM Rapid Test’s performance in detecting antibody responses following COVID-19 vaccination was evaluated in a cohort of 20 subjects that had no detectable levels of anti-SARS-CoV-2 antibodies before vaccination. All 20 subjects (100%) had their first positive result on the OnSite COVID-19 IgG/IgM Rapid Test 9 to 16 days post-vaccination, showing this test’s high sensitivity. Our ongoing.... Read Full Article >



Rapid identification and isolation of COVID-19 patients by prescreening VTM samples? The OnSite COVID-19 Ag Rapid Test by CTK might be the answer!

The performance of the OnSite® COVID-19 Ag Rapid Test by CTK was evaluated using sample material from nasopharyngeal swabs stored in viral transport media. The swabs were previously used to screen for SARS-CoV-2 using qPCR.  The OnSite® COVID-19 Ag Rapid Test sensitivity was between 86-90% depending on the viral load*. The study used leftover sample material selected from samples sent.... Read Full Article >



A Complete COVID-19 Management Solution

CTK is proud to provide a Complete COVID-19 Management Solution with the addition of our COVID-19 Antigen Rapid Test! See below for details!     OnSite  COVID-19 Ag Rapid Test Cat# R0182C Early diagnosis by detecting viral components within 1 week of symptoms High specificity ensures quick isolation of positive individuals Results in 15-20 minutes Doesn’t provide information on immune.... Read Full Article >



CTK Launched RaFIA Immunofluorescence immunoassay System!

CTK has recently launched their latest system, meeting market demand for quantitative rapid tests: CTK’s RaFIA System! This quantitative system is easy to use while offering a high level of sensitivity and a broad working range.  By pairing the RaFIA Test with our Immunofluorescence Analyzer and Incubator, we have created a closed system that is Accurate, Fast, Flexible, and User.... Read Full Article >



CTK and Employee Safety!

CTK’s vision is to provide quick and accurate solutions for every possible clinical scenario, and we continued to deliver on that mission with the development of our Aridia COVID-19 PCR kit for confirmation and our COVID-19 IgG/IgM Rapid Test for screening. This would not have been possible without the hard work and dedication of our employees. With our same level.... Read Full Article >



AACC Recommendations for SARS-CoV-2 Serology Testing

From AACC post, May 18, 2020 There is broad recognition that the unprecedented COVID-19 pandemic requires clinical laboratory testing as part of the worldwide response to this health crisis. To detect SARS-CoV-2—the virus that causes COVID-19—in infected individuals, the primary laboratory tool has been molecular diagnostic tests. While these tests inform clinicians of individuals who are currently infected by identifying.... Read Full Article >



CTK’s rapid test used in COVID-19 mass testing in the Philippines

From CDN digital facebook post, May 18, 2020 CEBU CITY, Philippines — The Office of the Presidential Assistance for the Visayas’ (OPAV) Project Balik-Buhay (PBB) has revealed the four brands of rapid antibody-based test kits that are used in running the blood samples from the mass testing in the cities of Cebu, Mandaue and Lapu-Lapu. These test kits brand include.... Read Full Article >



Evolved Value Proposition of the OnSite COVID-19 IgG/IgM Rapid Test

  Window for Detection of SARS-COV-2 Infection SARS-COV-2 is a new virus, emergent to humans. Since its first report in December 2019, we have gained tremendous understanding of its transmission, virus replication in the human body, immune response, pathogenesis, clinical symptoms, diagnosis, and treatment. Nandini Sethuraman et al1 concluded a most comprehensive and sound laboratory testing window with different technologies based.... Read Full Article >